Last reviewed · How we verify
Caspofungin Acetate 50 MG
At a glance
| Generic name | Caspofungin Acetate 50 MG |
|---|---|
| Sponsor | University Hospital, Tours |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pyrexia
- Hypokalaemia
- Vomiting
- Diarrhoea
- Constipation
- Nausea
- Hypotension
- Hypomagnesaemia
- Anaemia
- Abdominal pain
- Hypophosphataemia
- Hyperkalaemia
Key clinical trials
- PK/PD of Caspofungin in Children Severe Infection
- Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems (PHASE2)
- CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia (PHASE1, PHASE2)
- Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections (PHASE3)
- Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins (PHASE4)
- Empirical Versus Preemptive Antifungal Therapy (PHASE3)
- Pharmacokinetics of Caspofungin
- Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caspofungin Acetate 50 MG CI brief — competitive landscape report
- Caspofungin Acetate 50 MG updates RSS · CI watch RSS
- University Hospital, Tours portfolio CI